Invion Limited (ASX: IVX) announced on 21 April 2026 a significant milestone in the development of its lead asset INV043 — a photodynamic therapy candidate based on the Photosoft™ platform. The Safety Review Committee (SRC) overseeing Invion's Non-Melanoma Skin Cancer (NMSC) trial approved expanding the patient population to include Basal Cell Carcinoma (BCC), the largest and most prevalent subtype of skin cancer. The decision was informed by a second cohort of six squamous cell carcinoma (SCC) patient readouts that demonstrated no dose-limiting toxicities, reductions in lesion size (p<0.05), complete resolution in select cases, and consistent theragnostic fluorescence signals.

The BCC expansion is strategically important because BCCs account for approximately 80% of all skin cancers, dramatically increasing the addressable market and commercial optionality for INV043. BCCs are also difficult to grow in animal models, meaning human clinical data becomes particularly valuable for advancing to Phase II and attracting partnership interest. The decision represents both a scientific validation of the Photosoft mechanism of action and a commercial de-risking event for shareholders.

For ASX-listed life science investors, this update moves Invion from a single-indication SCC story to a broader NMSC platform, supported by a tolerable safety profile, early efficacy signals, and a dual-wavelength theragnostic capability. It also positions the Company ahead of an upcoming anogenital trial using the same topical formulation.

Key Facts

  • Company: Invion Limited
  • ASX Ticker: IVX
  • Announcement Date: 21 April 2026
  • Asset: INV043 (Photosoft™ photodynamic therapy)
  • Development Milestone: SRC approval to expand NMSC trial into Basal Cell Carcinoma (BCC) patients
  • Trigger: Second cohort of six SCC patients with encouraging safety and efficacy readouts
  • Key Efficacy Signal: Reductions in lesion size relative to baseline (p<0.05); complete resolution in select cases
  • Safety: No dose-limiting toxicities (DLTs); no observed pain during or after treatment
  • Market Relevance: BCCs account for ~80% of all skin cancers globally
  • Downstream Programs: Upcoming anogenital trial using the same topical formulation of INV043

Announcement Overview

Invion released the update under the title "Non-Melanoma Skin Cancer Trial Advances to Basal Cell Carcinoma (BCC) Cohort Following 2nd Set of Encouraging Safety & Efficacy Signals." The announcement details the SRC's formal approval for trial expansion and summarises Part 2 clinical observations that made the expansion possible. The SRC required satisfactory SCC safety results before BCC patients could be enrolled, and the second readout cleared that bar. Recruitment for the BCC cohort will now begin.

Importantly, early lesion-level observations include complete resolution in select patients, with durability under continued evaluation, and consistent fluorescence signals confirming the theragnostic nature of the Photosoft platform — red light (660nm) activates the therapeutic effect, while violet light (405nm) enables fluorescence-based visualisation of lesions.

Company Background

Invion Limited is an ASX-listed life sciences company leading global research and development of Photosoft™ technology, a next-generation photodynamic therapy (NGPDT) platform. Invion holds the global exclusive licence to Photosoft for multiple cancer and non-cancer disease indications. The Company is pursuing indications across oncology (including non-melanoma skin cancers and anogenital cancers), atherosclerosis, and infectious diseases such as antibiotic-resistant bacterial, fungal and viral infections. Its head office is in Melbourne, Victoria.

Detailed Analysis

Why BCC Matters Commercially

BCCs represent approximately 80% of all skin cancers globally, making the BCC indication substantially larger than SCC by patient volume. Current standard of care — including surgical excision, topical therapies and conventional photodynamic therapy (PDT) — is effective but often associated with pain, scarring and recurrence. A novel PDT that delivers durable responses with no observed pain could represent a material clinical and commercial advance.

The Safety and Efficacy Picture

Across the second SCC cohort, Invion reports no DLTs and a strong tolerability profile. Clinician feedback indicates no pain during or after treatment — a noteworthy contrast to approved PDT therapies where treatment-associated pain is a recognised patient-compliance issue. Efficacy signals — statistically significant lesion size reductions and complete resolution in select patients — are consistent with the mechanism of action: targeted reactive oxygen species generation under red-light activation, selectively damaging cancer cells while sparing healthy tissue.

Theragnostic Advantage

Photosoft's dual-wavelength theragnostic capability is operationally compelling: violet light (405nm) enables fluorescence-based lesion visualisation, which can help clinicians better define treatment margins, while red light (660nm) delivers the therapeutic effect. This "see-and-treat" feature could support adoption in real-world settings and underpin IP differentiation against more conventional PDT systems.

Strategic Significance

The BCC expansion unlocks three strategic levers for Invion: (1) it broadens INV043's addressable market from the SCC subset to the full NMSC opportunity; (2) it generates human BCC data that is difficult to replicate preclinically, strengthening the pre-Phase II evidence package; and (3) it reinforces the platform's versatility, which can be leveraged for the upcoming anogenital trial and, longer term, for infectious diseases and other oncology indications.

Market & Investor Impact

Micro-cap biotech names respond strongly to trial design expansions and safety-driven cohort approvals. While the announcement does not include full Phase II timelines or partnership updates, it materially increases the probability of commercially relevant outcomes. The Company has indicated further updates will be provided as the BCC cohort progresses. Investors should expect newsflow around recruitment milestones, interim safety signals, and eventually Phase II strategy.

What This Means for Investors

IVX shareholders should track: (1) initiation of BCC patient recruitment and pace of enrolment; (2) further safety and efficacy readouts from the SCC cohort, particularly durability data; (3) progression of the anogenital trial using the same topical formulation; and (4) any partnership, licensing or regulatory engagement updates. As with any small-cap biotech, position sizing and risk tolerance are critical — clinical development remains a binary endeavour.

Risks and Opportunities

Risks

  • Early efficacy signals may not persist in larger cohorts or across BCC patients.
  • Recruitment and clinical site execution risk could delay readouts.
  • Regulatory pathway to approval for novel PDT therapies is multi-year.
  • Funding risk: biotech development is capital-intensive and future raises are likely.

Opportunities

  • Expansion into BCC dramatically enlarges the addressable market.
  • Pain-free treatment profile could support rapid clinician adoption.
  • Theragnostic capability offers IP and clinical differentiation.
  • Platform optionality in anogenital cancers, atherosclerosis and infectious diseases.

Key Takeaways

  • SRC approved expansion of the NMSC trial into BCC patients.
  • Second SCC cohort produced no DLTs and statistically significant lesion reductions.
  • Complete resolution observed in select SCC patients; durability under evaluation.
  • BCCs represent ~80% of all skin cancers, expanding INV043's market.
  • Theragnostic dual-wavelength capability differentiates Photosoft from approved PDTs.

Bottom Line

The 21 April 2026 announcement is a meaningful clinical and commercial milestone for Invion Limited (ASX: IVX). By advancing INV043 into BCC patients on the back of reassuring safety and encouraging efficacy data, Invion has broadened the addressable market, validated the Photosoft theragnostic platform, and laid the groundwork for a stronger Phase II strategy and its upcoming anogenital trial.

Disclaimer

This article is based solely on the corresponding ASX announcement and is for informational purposes only. It does not constitute financial, investment, legal, or tax advice. Investors should conduct their own due diligence and consult a licensed financial adviser before making investment decisions. Past performance is not indicative of future results.